CLDI (Calidi Biotherapeutics) Additional Paid-In Capital: $153.05 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLDI Calidi Biotherapeutics Inc CLDI
11 GF Score
Price $1.24
! 1 Warning Sign
View Full Analysis

What is Calidi Biotherapeutics Additional Paid-In Capital?

Calidi Biotherapeutics CLDI -5.34% 11 Additional Paid-In Capital is $153.05 Mil as of Jun. 2026. GuruFocus rates CLDI with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.


Calidi Biotherapeutics's quarterly additional paid-in capital increased from Dec. 2025 ($145.39 Mil) to Mar. 2026 ($150.69 Mil) and increased from Mar. 2026 ($150.69 Mil) to Jun. 2026 ($153.05 Mil).

Calidi Biotherapeutics's annual additional paid-in capital increased from Dec. 2023 ($91.38 Mil) to Dec. 2024 ($123.28 Mil) and increased from Dec. 2024 ($123.28 Mil) to Dec. 2025 ($145.39 Mil).

Calidi Biotherapeutics Additional Paid-In Capital Related Terms

Calidi Biotherapeutics Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Calidi Biotherapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Calidi Biotherapeutics Additional Paid-In Capital Chart

Calidi Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
Get a 7-Day Free Trial 13.32 19.93 91.38 123.28 145.39

Calidi Biotherapeutics Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 134.19 144.50 145.39 150.69 153.05
CLDI
11GF Score
Calidi Biotherapeutics Inc CLDI
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Calidi Biotherapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $153.05 Mil mean?
Calidi Biotherapeutics (CLDI) has a Additional Paid-In Capital of $153.05 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Calidi Biotherapeutics and its competitors.
Is Calidi Biotherapeutics' Additional Paid-In Capital too high?
Calidi Biotherapeutics' current Additional Paid-In Capital is $153.05 Mil. Overall, Calidi Biotherapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Calidi Biotherapeutics' Additional Paid-In Capital compare to ARTL and CRIS?
Calidi Biotherapeutics' Additional Paid-In Capital of $153.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Biotechnology company?
A good Additional Paid-In Capital depends on the Biotechnology industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Calidi Biotherapeutics and its competitors. Calidi Biotherapeutics's current Additional Paid-In Capital is $153.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Calidi Biotherapeutics stock overvalued right now?
Calidi Biotherapeutics (CLDI) has a current Additional Paid-In Capital of $153.05 Mil. The current Additional Paid-In Capital is $153.05 Mil. Calidi Biotherapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Calidi Biotherapeutics (CLDI), the current Additional Paid-In Capital is $153.05 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Calidi Biotherapeutics Business Description

Address 4475 Executive Drive, Suite 200, San Diego, CA, USA, 92121
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
11GF Score

Get the complete analysis for CLDI

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.24
Price